

Please type a plus sign (+) inside this box

531 Re: PCT/CA 25 MAY 2001

5010-107-02  
PTO/SB/08A (10-96)

110,500 USA (18-30)  
31/99 OMV 0651-0031

Approved for use through 10/31/99. OMB 0651-003  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Collection of information unless it contains a valid OMB control number.

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of 9

<i>Complete if Known</i>	
Application Number	09/856803
Filing Date	05/25/2001
First Named Inventor	Stephen B. Liggett
Group Art Unit	
Examiner Name	
Attorney Docket Number	MWH-0029US

U.S. PATENT DOCUMENTS

#### FOREIGN PATENT DOCUMENTS

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not used.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached *Kinds of U.S. Patent Documents*. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indicator of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

25 MAY 2001

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10/31/09. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

097856803

Application Number	
Filing Date	05/25/2001
First Named Inventor	Stephen B. Liggett
Group Art Unit	
Examiner Name	
Attorney Docket Number	MWH-0029US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Ch	BA	GREEN, S.A., J. TURKI, P. BEJARANO, I.P. HALL, AND S.B. LIGGETT, "Influence of b2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells," American Journal of Respiratory Cell and Molecular Biology, Vol. 13, p.25-33, 1995.
	BB	HALL, I.P., A. WHEATLEY, P. WILDING, AND S.B. LIGGETT, "Association of the Glu27 b2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects," Lancet, Vol. 345, p. 1213-1214, 1995.
	BC	LIGGETT, S.B., "Polymorphisms in the B2-Adrenergic Receptor and Asthma," American Journal of Respiratory and Critical Care Medicine, Vol. 156, p.S156-S162, 1997.
	BD	MARTINEZ, F.D., P.E. GRAVES, M. BALDINI, S. SOLOMON, AND R. ERICKSON, "Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing," Journal of Clinical Investigation, Vol. 100, p. 3184-3188, 1997.
	BE	MCGRAW, D.W., S. FORBES, L. KRAMER, AND S.B. LIGGETT, "Polymorphisms in the 5' Leader Cistron of the Human Beta2-Adrenergic Receptor Regulate Receptor Expression," Journal of Clinical Investigation, Vol. 102, p. 1927-32, 1998.
	BF	PAROLA, A.L. AND B.K. KOBILKA, "The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis," Journal of Biological Chemistry, Vol. 269, p. 4497-4505, 1994.
	BG	TURKI, J., J. LORENZ, S.A. GREEN, E.T. DONNELLY, M. JACINTO, AND S. LIGGETT, "Myocardial Signaling Defects and Impaired Cardiac Function of a Human B2-Adrenergic Receptor Polymorphism Expressed in Transgenic Mice," Proceedings of the National Academy of Sciences, Vol. 93, p.10483-88, 1996.
	BH	TURKI, J., J. PAK, S.A. GREEN, R.J. MARTIN, AND S. LIGGETT, "Genetic Polymorphisms of the B2-Adrenergic Receptor in Nocturnal and Nonnocturnal Asthma," Journal of Clinical Investigation, Vol. 95, p. 1635-1641, 1995.
Ch	BI	YAMADA K, ET AL., "Polymorphism in the 5'-leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2 diabetes," Journal of Clinical Endocrinology & Metabolism, Vol. 84, p. 1754-1757, 1999.

Examiner Signature	<i>John Wm</i>	Co-Examiner	12-23-02
--------------------	----------------	-------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.